Description
MT-2 (Melanotan 2 Acetate) is a cyclic lactam-bridged heptapeptide with the sequence Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH₂ and a molecular weight of approximately 1024 Da. It was developed at the University of Arizona during research into superpotent, enzymatically resistant melanocortin analogs for studying skin pigmentation pathways. Unlike the linear peptide afamelanotide (MT-1), MT-2’s cyclic structure confers resistance to enzymatic degradation and broad receptor engagement.
This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.
Key Research Focus
MT-2 has been investigated in preclinical research exploring its roles in:
- Melanocortin Receptor Pharmacology: MT-2 is a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. Receptor binding studies demonstrate Ki values of 0.67 nM for MC1R, 6.6 nM for MC4R, 34 nM for MC3R, and 46 nM for MC5R, yielding a distinct multi-receptor selectivity fingerprint that differs substantially from MC1R-selective compounds. Functional studies in B16-F10 murine melanoma cells show that MT-2 (10 nM) produces 2.3-fold greater melanin content compared to the MC4R-preferring analog PT-141 (bremelanotide) at identical concentrations.
- Melanogenesis and Pigmentation: Activation of MC1R on melanocytes triggers Gs-coupled adenylate cyclase signaling, increasing intracellular cAMP and driving MITF-mediated transcription of melanogenic enzymes. Research indicates that MT-2-bound MC4R complexes continue signaling from endosomal compartments after receptor internalization, contributing to prolonged physiological efficacy.
- Central Nervous System Effects: MT-2 crosses the blood-brain barrier and engages central MC3R/MC4R. Preclinical studies in rodent models demonstrate pro-erectile effects via MC4R activation and satiety signaling. In zebrafish, percutaneous MT-2 (20 µM) reversed high-fat diet-induced cognitive impairment, anxiety, and reduced exploratory behavior. In a maternal immune activation mouse model, intracerebroventricular MT-2 (2.5 µg/day, 7 days) increased sociability index from 3.1 to 26.3.
- Metabolic and Appetite Modulation: Bilateral microinjection of MT-2 (0.1–1 nM) into the nucleus accumbens of fasted C57BL/6J mice significantly reduced food intake for up to 24 hours. This anorectic effect is attributed to MC4R activation in hypothalamic circuits.
Documented Safety Risks (Case Literature)
Published case reports document serious adverse events associated with unregulated MT-2 use. Ischemic priapism requiring surgical decompression has been reported, including a case of a 41-year-old man with a 22-hour erection requiring drainage of 700 mL of blood. Cutaneous melanoma was diagnosed in a 20-year-old woman following a 3–4 week course of self-injections combined with sunbed use. Oral mucosal malignant melanoma was reported in a 22-year-old woman after using MT-2 nasal spray. Exogenous hypercortisolism with hypertension and impending diabetic ketoacidosis occurred in a type 1 diabetic patient, with ACTH assay cross-reactivity documented. Other reported events include rhabdomyolysis, renal infarction, and posterior reversible encephalopathy syndrome (PRES).
Regulatory Status
MT-2 is not FDA-approved for any indication and has never received regulatory approval in any jurisdiction. It is not eligible for pharmaceutical compounding under Section 503A or 503B. As of the 2026 WADA Prohibited List, non-approved peptide hormones and their analogs are prohibited under Section S2. Health authorities including Australia’s TGA and Health Canada have banned the drug.
Product Specifications
- Form: Lyophilized Powder (Sterile)
- Purity: ≥98% (HPLC Verified)
- Molecular Formula: C₅₀H₆₉N₁₅O₉ (free base)
- Molecular Weight: 1024.19 Da
- CAS Number: 121062-08-6 (free base); 1036322-26-5 (acetate salt)
- Sequence: Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH₂ (2→7 lactam)
- Storage: Store desiccated at -20°C to -80°C. Protect from light. Reconstituted stock stable for 14–30 days at 2–8°C.
- Solubility: Sparingly soluble in aqueous buffers; soluble in DMF (~30 mg/mL), DMSO (~15 mg/mL), water (~5–6.7 mg/mL with sonication).
- Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use.
Why Choose MT-2?
MT-2 offers a research tool for studying non-selective melanocortin receptor activation, with well-characterized pharmacology and distinct selectivity differences from MC1R-preferring (afamelanotide) and MC4R-preferring (bremelanotide) analogs. Its cyclic structure provides enhanced stability compared to linear α-MSH analogs, making it suitable for in vitro and in vivo studies requiring sustained receptor engagement. Researchers should note the significant limitations: no clinical trial data supports safe human use, gray-market products have documented purity variability (labeled 10 mg vials containing 4.32–8.84 mg actual peptide), and serious adverse events including melanoma and priapism are documented in the case literature.



